摘要
目的：探讨恩替卡韦对乙型肝炎病毒（HBV）DNA阳性肺结核患者肝功能干预作用。方法：将165例HBVDNA阳性肺结核患者随机分成治疗组81例和对照组85例。观察2组病例肝损发生率、发生时间、损伤程度，并将所得数据作统计学处理。结果：治疗组肝损发生率低（18．5％），出现时间晚（30-150）d，肝损程度轻，恢复快（17±3．8）d，完成抗结核治疗时间相对较短（210±16．3）d，与对照组相比差异有显著性（P〈0．01）。结论：恩替卡韦对HBVDNA阳性肺结核患者肝功能有明显干预作用，可显著降低结核药物对此类患者的肝损伤。
OKIECTIVE To explore the effects of entecavir（ETV）on the liver function of tuberculosis patients with HBV DNA positive. METHODS 165 pulmonary tuberculosis patients with HBV DNA positive were randomly divided into treatment group consisted of 81 and control group consisted of 85 patients. The liver injury incidence rate and time, degree, reviving nor mality time,course of anti-tuberculosis treatment completed and the change of hepatitis B virus marker were investigated. RE- SULTS The liver injury incidence rate of treatment group was mild and lower（18. 5%）and the occurrence time was late（30-- 150）days, the recovery （17± 3.8 days） and antituberculosis treatment course（210 ± 16.3 days） were shorter than those of the control group （P〈0. 01）. CONCLUSION Entecavir had the obvious intervention effects on liver function of the pulmonary tuberculosis patients with HBV DNA positive. It can significantly reduce the injury of anti-turberculosis drugs to the liver function.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2014年第3期226-228,共3页
Chinese Journal of Hospital Pharmacy
